Lantern Pharma Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Lantern Pharma Inc. (LTRN) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $285.26 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- Lantern Pharma Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $285.26K, a 77.59% increase year-over-year.
- Lantern Pharma Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $262.92K, a 77.95% increase year-over-year.
- Lantern Pharma Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $143.69K, a 19.80% decline year-over-year.
- Lantern Pharma Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $160.63K, a 19.72% increase year-over-year.
- Lantern Pharma Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $650.88K, a 0.19% decline from fiscal 2024.
- Lantern Pharma Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $652.09K, a 35.91% decline from fiscal 2023.
- Lantern Pharma Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $1.02M, a 14.34% decline from fiscal 2022.
- Lantern Pharma Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $1.19M, a 23.52% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $285.26K 10-Q · filed 2026-08-14 | $548.17K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $262.92K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $650.88K 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $143.69K 10-Q · filed 2025-11-12 | $304.31K derived: sum of 2 quarters · filed 2026-08-14 | $452.06K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $160.63K 10-Q · filed 2026-08-14 | $308.38K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $147.75K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $652.09K 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $179.17K 10-Q · filed 2025-11-12 | $313.34K derived: sum of 2 quarters · filed 2025-11-12 | $447.39K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $134.17K 10-Q · filed 2025-11-12 | $268.23K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $134.06K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $1.02M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $190.75K 10-Q · filed 2024-11-07 | $583.14K derived: sum of 2 quarters · filed 2024-11-07 | $916.67K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $392.39K 10-Q · filed 2024-11-07 | $725.92K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $333.53K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $1.19M 10-K · filed 2024-03-18 | |||
| 2022-09-30 | $301.11K 10-Q · filed 2023-11-08 | $590.65K derived: sum of 2 quarters · filed 2023-11-08 | $857.65K derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $289.53K 10-Q · filed 2023-11-08 | $556.54K derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $267.00K 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $961.54K 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $224.41K 10-Q · filed 2022-11-07 | $470.10K derived: sum of 2 quarters · filed 2022-11-07 | $715.62K derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $245.68K 10-Q · filed 2022-11-07 | $491.20K derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $245.52K 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |